EP3818181A1 - Procede et dispositif pour la detection et differenciation de mutations ponctuelles chez des microorganismes par oligochromatographie - Google Patents
Procede et dispositif pour la detection et differenciation de mutations ponctuelles chez des microorganismes par oligochromatographieInfo
- Publication number
- EP3818181A1 EP3818181A1 EP19734437.7A EP19734437A EP3818181A1 EP 3818181 A1 EP3818181 A1 EP 3818181A1 EP 19734437 A EP19734437 A EP 19734437A EP 3818181 A1 EP3818181 A1 EP 3818181A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hybridization
- amplification
- nucleotide
- sequences
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a method for the detection and differentiation of point mutations in microorganisms, in particular a bacterium, comprising a step of amplification of one or more DNA targets, whether or not preceded by a step of transcription inverse of one or more RNA, and followed by a step of detection by oligochromatography of the amplified products and of differentiation (or discrimination) of point mutations (mutations by substitution, insertion or deletion of nucleic bases).
- Point mutations or (mono) nucleotide polymorphisms, can be responsible for pathologies in living beings or even allow certain microorganisms to adapt to an unfavorable environment, as in the case of the appearance of resistance to anti-infective agents.
- nucleotide polymorphisms that is to say to detect the insertion or deletion of a nucleotide base, as well as the substitution of a "wild" type nucleotide base by another nucleotide base (mutated), capable, possibly, of conferring a new phenotype.
- polymorphic variants or subpopulations can also coexist in a single individual. For example, some bacteria resistant to antibiotics coexist with sensitive bacteria. The detection of these different sub-populations can have consequences on the severity of the disease or on the choice of treatment to be administered to the patient.
- nucleotide polymorphisms in a coding sequence one of the major difficulties is to be able not only to identify the region or the position in the genome of the mutated nucleic base, but also, in the case of coding regions, to determine specifically the amino acid modified by the point mutation. Indeed, a single position of the genome can present different nucleotide polymorphisms, generating where appropriate the synthesis of different amino acids. In some cases, the response to the severity of the pathology or the sensitivity or resistance to the anti-infective agent is dependent on the amino acid synthesized. It is therefore essential to be able to identify the modified nucleotide base with respect to the wild-type coding sequence.
- This method allows both the multiplex amplification of targets and the specific detection of point mutations within at least nine mutational positions on each amplified target nucleotide sequence (also called amplicon) from a single sample of nucleic acids.
- This method allows in particular:
- nucleotide probes complementary to the mutated target nucleotide sequences capture probes immobilized on an oligochromatography support
- Another advantage of the method of the invention is its speed, since it can be executed quickly, in less than 90 minutes, preferably in less than 60 minutes, or even in preferred conditions in less than 30 minutes.
- the hybridization and washing steps of the invention are carried out in 20 minutes or less.
- An additional advantage of the method according to the invention is its simplicity, since it can easily be carried out in a maximum of 2 stages, preferably in a single stage.
- this method represents a diagnostic tool for (mono) nucleotide polymorphisms in the medical field and more particularly in that of infectious diseases and antibiotic resistance.
- the present invention relates to a method of detection and differentiation by oligochromatography of at least one point mutation in the genome of a microorganism, preferably a bacterium, present in a biological sample comprising the following steps:
- a- amplification of at least one target nucleotide sequence said target nucleotide sequence being capable of carrying a point mutation, that is to say of presenting, at a given position, the deletion of a nucleotide, the substitution of this nucleotide with another nucleotide or the insertion of a nucleotide just before or just after said position;
- step b detection by oligochromatography, among the amplified target nucleotide sequences obtained in step a) of wild-type nucleotide sequences or carriers of a point mutation, by a hybridization carried out at a hybridization temperature of at least 55 ° C., preferably between 55 and 80 ° C, said target nucleotide sequences amplified with several capture probes which contain 18 to 35 bases immobilized on a membrane, one of these capture probes being complementary and specific to part of the sequence wild-type nucleotide, each of the others being complementary and specific to a part of nucleotide sequence comprising at least one point mutation, and the detection of the amplified target nucleotide sequences hybridized on the capture probes.
- oligochromatography it is understood within the meaning of the present invention a method of detection and differentiation of nucleic acids present in a liquid by migration of this liquid by capillary action in an appropriate support, called oligochromatographic support, to allow their hybridization to specific capture probes immobilized on the oligochromatographic support and therefore allow their separation from the liquid.
- an oligochromatographic support has the capacity to spontaneously transport a fluid by capillary action. Oligochromatography must therefore be considered, in the context of the present invention, as being a method of dynamic transport of the liquid, preferably a method of lateral flow.
- the support is preferably a porous membrane.
- the oligochromatography technique offers several advantages such as simplicity and speed of production, unlike certain techniques known in the state of the art such as detection by "microarray” which may require numerous steps as well only specialized and expensive equipment.
- the transposition of a method carried out on a microarray type chip to an oligochromatographic support is not easy, however, as the techniques are different.
- a method for detecting viruses or bacteria by oligochromatography is known from document WO2004099438A1.
- the method according to this document does not allow precise identification of the position or the mutated nucleotide base, unlike the method according to the present invention which makes it possible to detect and identify point mutations, especially to differentiate and d '' identify different point mutations at the same position.
- hybridization temperature of at least 55 ° C. and capture probes which contain from 18 to 35 bases makes it possible to carry out the hybridization without the use a specific hybridization buffer.
- hybridization according to the method of the invention can be carried out directly from the PCR product in its amplification buffer (solution comprising the amplified target nucleotide sequences obtained in step a)).
- the membrane can be deposited on a rigid structural support, preferably a rigid structural support of the tab type, in order to maintain it and facilitate its handling.
- the rigid structural support preferably the rod, comprises a lower absorbent which is present upstream of the membrane relative to the direction of migration by capillarity of the PCR product and corresponds to a region d application where the PCR product obtained in step a) of the method is deposited.
- the rigid structural support preferably the rod, comprises an upper absorbent which is present downstream of the membrane relative to the direction of migration by capillarity of the PCR product and corresponds to a region harvest where the part of the PCR product not captured in step b) of the method is recovered.
- the membrane is considered to be the detection region, that is to say the region where the capture probes are immobilized.
- the membrane can be of different natures; it may for example be a nitrocellulose, cellulose, cellulose acetate, nylon, acrylic and nylon copolymer membrane.
- the membrane is a nitrocellulose membrane.
- the support comprises a micro-pillar network.
- the hybridization is carried out using the same buffer as that obtained during the amplification of step a) of the method according to the invention.
- the amplification and the hybridization are carried out in the same buffer, also called, in the context of the present invention, the amplification buffer.
- the method according to the present invention comprises:
- a- amplification of at least one target nucleotide sequence in an amplification buffer said target nucleotide sequence being capable of carrying one or more point mutation (s), that is to say of presenting, at one or more given position (s), the deletion of a nucleotide, the substitution of this nucleotide by another nucleotide or the insertion of a nucleotide just before or just after said position;
- the determination of a hybridization temperature of at least 55 ° C. allows nucleotide discrimination via the temperature, which makes the use of a specific hybridization buffer unnecessary.
- the hybridization temperatures specifically disclosed are 42 ° C and 37 ° C, respectively. According to these prior documents, at least two successive washings must be carried out after the hybridization step in a specific hybridization buffer to ensure the specificity of the hybridization of a capture probe.
- the hybridization of step b) is carried out in the amplification buffer of step a) at a temperature of at least 55 ° C.
- the biological sample consists of nucleic acids extracted from biological samples (humans, animals, plants, etc.); it may in particular consist of a sample extracted from an animal or from an individual such as a mammal, more particularly from a human, or from a food composition.
- the biological sample is preferably lysed in a chemical lysis buffer or by thermal lysis or by mechanical lysis or by enzymatic lysis before being extracted by manual or automated extraction methods generally combining two to three of the following steps such as retention or separation by affinity on a chromatographic column or magnetic beads, chemical precipitation, centrifugation ...
- the target nucleotide sequences can be DNA sequences, in particular single-stranded or double-stranded or partially double-stranded DNA sequences, as well as cDNA sequences obtained by reverse transcription of RNA sequences.
- the method according to the invention can comprise an optional step, prior to step a), corresponding to the reverse transcription of the RNA contained in the sample.
- the amplified target sequences have a size of between 50 and 200 bases, in particular from 70 to 150 bases.
- Step a) of amplification can be carried out by any method known to those skilled in the art; more particularly, it can be carried out by PCR or by isothermal amplification, in particular by the LAMP (Loop-Mediated Amplification) method (Notomi et al., Nucleic acid Res., 2000, 28, e63) or RPA (Recombinase Polymerase Amplification) (Piepenburg et al., PLOS Biol., 2006, 4 (7 ), e204) or NASBA (Nucleic Acid sequence-based amplification) (Guatelli et al., PNAS, 1990, 87 (5), 1874-1878).
- LAMP Loop-Mediated Amplification
- RPA Recombinase Polymerase Amplification
- NASBA Nucleic Acid sequence-based amplification
- MLPA Multiplex Ligation-dependent Probe Amplification
- the amplification step is carried out by PCR.
- the reaction mixture for amplification also called the amplification buffer, can contain several reagents such as a buffer, enzymes, deoxynucleotides triphosphates (dNTPs), additives, and in particular several pairs of primers for the simultaneous amplification of multiple sequences in a single sample.
- a buffer such as a buffer, enzymes, deoxynucleotides triphosphates (dNTPs), additives, and in particular several pairs of primers for the simultaneous amplification of multiple sequences in a single sample.
- dNTPs deoxynucleotides triphosphates
- the two stages of reverse transcription and amplification by PCR can be carried out either in closed reaction tubes, inserted in a programmable instrument which heats and cools a stationary reaction chamber (such as a thermocycler), or in a microfluidic device with single use in which the reaction mixture circulates on static zones each having a defined temperature.
- reverse transcription is performed at a single temperature before successive heating and cooling cycles allow targets to be multiplied (amplified) by PCR reaction.
- these steps are carried out in continuous flow in a microfluidic system as described in European Patent EP 2 870 260 or in patent application EP 3 075 451.
- nucleotide sequences used as primers for the amplification preferably by PCR, is made according to the target nucleotide sequence (s) to be amplified and detected.
- the selection of these primers is within the reach of those skilled in the art, as well as their possible labeling with elements such as metallic particles, preferably gold particles, colloids, polystyrene particles, colored particles. , (para) -magnetic particles or fluorescent elements or any other marker allowing detection.
- the amplified target nucleotide sequence can be labeled, directly or indirectly, with different detection markers, preferably fluorophores (or fluorescent elements) or nanoparticles such as colloidal gold.
- the amplicon can be labeled (i) either from the amplification stage by the use of an amplification primer marked with a fluorophore ( Figure IA), (ii) or after resuspension of a probe fluorescent or a probe coupled to a colloidal gold conjugate ( Figure IB) deposited at the region application of the oligochromatography support, the sequence of which is different from the sequence of the immobilized capture probe and complementary to part of the amplified target nucleotide sequence, (iii) either by the incorporation of a primer marked with a hapten (for example DIG, DNP or FAM) and the resuspension of the receptor for this hapten, a receptor itself coupled to a detection marker ( Figure IC).
- a hapten for example DIG, DNP
- the marker is a fluorescent marker, preferably consisting of cyanine (Cy5) or of a marker having similar fluorescent properties.
- Markers having different types of staining or different wavelengths of fluorescence can be used for the labeling of the amplified target nucleotide sequences so as to facilitate their simultaneous or consecutive detection on the support, each color being specific for a sequence or a group of amplified target nucleotide sequences initially present in the test sample, their colorimetric detection can thus be obtained by means known to those skilled in the art.
- the number of different nucleotide sequences which can be detected by the method according to the invention can be adapted according to the needs of the application.
- the method of the invention is modular and makes it possible to adapt the number of capture probes present on the oligochromatographic support according to the number of target nucleotide sequences to be detected.
- between about 2 sequences and about 50 target nucleotide sequences preferably between about 4 sequences and about 40 target nucleotide sequences are amplified and detected in the same sample.
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45 or 50 target sequences are amplified and detected in the same sample.
- the capture probes used to detect by hybridization the target nucleotide sequences amplified in step a), have a length of between 18 and 35 bases, preferably between 20 and 32 bases. Their sequence is defined according to the region in which the point mutation is sought.
- the capture probes according to the invention have a size of 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 bases.
- the capture probes can be formed from purine, pyrimidine, degenerate, universal, or LNA (lock nucleic acid), ANA (altritol nucleic acid), HNA (hexitol nucleic acid), etc. nucleotide bases. nucleic acid type PNA (peptide nucleic acid) but which can be paired with nucleotide sequences or combinations of these different types of bases.
- the melting temperature (Tm) of the capture probes is between 68 and 80 ° C, preferably between 70 and 78 ° C.
- the melting temperature is also well known as the melting temperature.
- the Tm of the capture probes is calculated according to the “Nearest-neighbor two-state” model.
- the capture probes may be entirely specific for a target sequence or contain, in addition to the sequence defined according to the region in which the point mutation is sought (for example in addition to their 18 to 35 bases), spacers (“ spacers ”) of nucleotide or chemical nature.
- the nucleotide type spacer is a sequence of at least 2 T (thymine), preferably between 5T and 8T, and the chemical type spacer is a carbon type chain of at least 3 carbons and a maximum of 12 carbons.
- the capture probes are immobilized on the support, preferably on an oligochromatography membrane, allowing the capture or the hybridization of the amplified target nucleotide sequences.
- the capture probes specific to each point mutation, whether or not starting with a spacer, are immobilized on the support, preferably on an oligochromatography membrane in the form of points ("spotted") ( Figure 2), in particular via covalent bonds or via a carrier molecule to facilitate attachment to the support and accessibility of the probe.
- the carrier molecule is added to the nucleotide sequence of the probe, regardless of the presence of the spacer. This fixation can be direct or indirect; in the latter case, the capture probe is coupled to a first molecule, such as biotin, itself fixed on the membrane by a second complementary protein molecule, such as avidin, streptavidin or derived molecules.
- the membrane whether or not held on the rigid support, may be in the form of a strip.
- a strip according to the invention can be dipped in a reaction tube or placed in a microfluidic system.
- a strip according to the invention has a length of 40 to 60 mm and a width of 4 to 10 mm. More particularly, a strip according to the invention has a length of 57 mm and a width of 5 mm.
- the support can also be a microfluidic detection chip made of a cycloolefin polymer.
- the hybridization temperature is at least 56 ° C, preferably at least 57 ° C, preferably at least 58 ° C, even more preferably at least minus 59 ° C, even more preferably at least 60 ° C.
- the hybridization temperature is at least 60 ° C, preferably between 60 ° C and 80 ° C, preferably between 60 ° C and 73 ° C, again more preferably between 62 ° C and 73 ° C.
- the hybridization temperature is between 67 ° C and 73 ° C.
- the different steps of the method according to the invention can be carried out either in a single microfluidic device, or in tubes. closed reactions then requiring a detection step, separate from the amplification, on the oligochromatographic support.
- the method is implemented in a microfluidic device, as described in European Patent EP 2 870 260 and shown in Figure 3; this microfluidic device is inserted into dedicated equipment allowing the temperatures of reverse transcription, PCR and detection to be managed.
- the flow of the reaction mixture is conditioned by a peristaltic pump and the detection zone is read using a camera.
- Software for analyzing the signals observed makes it possible to differentiate the (mono) nucleotide polymorphisms.
- the method according to the invention is carried out using reaction tubes which are inserted into a thermocycler allowing the possible RT-PCR and PCR to be carried out.
- the amplified target nucleotide sequences are then detected after migration on the oligochromatographic support, on which the capture probes are immobilized. Reading the optical zone and analyzing the signals are then carried out using a reader and analysis software.
- the hybridization is followed by washing with a migration buffer.
- a migration buffer In particular, after the step of capturing the target nucleic acid sequences amplified by hybridization with the immobilized capture probes, the oligochromatographic support is washed with a buffered solution aimed at eliminating the primers marked in excess and the aspecific hybridizations.
- the buffered solution can be introduced either at the level of the buffer reservoir in the microfluidic device as described in ( Figure 3, reference 12), or at the bottom of a tube in the case of vertical oligochromatography.
- the terms “migration buffer” and “buffered wash solution” are used interchangeably. Buffered solution refers to buffered washing solution unless expressly stated otherwise.
- the migration buffer is different from the amplification buffer.
- the migration buffer is a phosphate-based buffer supplemented with TRIS, with salts (KCI and MgCI 2 ) and with saturants (casein hydrolyzate and threalose).
- the solution buffer is introduced into the buffer reservoir of the microfluidic device ( Figure 3, reference 12)
- the buffered solution is subjected to the temperatures first of the reverse transcription, of the PCR, then of the hybridization at the level of the oligochromatographic device.
- the tube containing the buffered washing solution is heated to the temperature allowing hybridization between the nucleotide probes immobilized on the oligochromatography device and the amplified nucleotide sequences.
- the support is washed with the buffered solution, for example for 5, 10, 15, 20 or 30 minutes, or when the dedicated equipment establishes the best signal / background noise ratio at each probe spot. nucleotide.
- the detection zone is exposed to the light source of dedicated equipment or a microscope in order to detect and quantify the signal either of a fluorescent marker or of a detectable element in the visible light spectra such as colloidal gold beads.
- the exposure time is adapted to the method used, for example, it can be between 1 and 5000 ms, in particular between 50 ms and 1500 ms.
- the signal intensities are measured at each position (“spot”) where a nucleotide capture probe is immobilized on the oligochromatographic device; this is the specific signal, and around each position it is the background noise.
- this equipment positions an analysis grid allowing the automatic quantification of the light signal for each spot and for the background noise signal around each spot.
- the signal strength is higher when the probe recognizes its homologous sequence in the amplicon.
- the amplicon is wild type, the wild probe will be brighter. For example, if in the wild sequence the nucleotide in position X is G then it is the spot with the probe carrying a C complementary to the G in position X which will be brighter.
- the amplicon is of the mutated type, the mutated probe will be brighter. For example, if in the mutated sequence the nucleotide in position X is replaced by a T (G> T) then it is the spot with the probe carrying an A at position X which will be brighter.
- an analysis algorithm facilitates the interpretation of the results.
- the point mutation to be detected is likely to be present in the genome of a microorganism, in particular a bacterium or a virus.
- the method is intended to detect a point mutation in the bacterial genome of Mycobacterium tuberculosis.
- the method is intended to detect a point mutation in the viral genome of the genus Enterovirus.
- bacterial genome means the bacterial chromosome and the natural bacterial plasmids.
- a point mutation represents a deletion, insertion or substitution of a nucleotide in a codon of the bacterial genome which can lead to the expression of a protein having an amino acid modified compared to the wild-type sequence of this protein.
- the wild sequence of a gene or a protein is that present mainly in nature.
- the method according to the invention allows the detection of a point mutation associated with resistance to an antibiotic.
- the antibiotic can be chosen from the following families: beta-lactams, glycopeptides, aminoglycosides, macrolides, phenicolics, cyclins, fusidic acids, oxazolidinones, quinolones, sulfonamides and trimethoprim, nitrated products ( nitrofurans and nitroimidazoles), anti-tuberculosis drugs in particular, it may be a point mutation associated with resistance in Mycobacterium tuberculosis to rifampicin, isoniazid, pyrazinamide, ethanbutol and fluoroquinolones ...
- Resistance to first-line antibiotics can result from a point mutation localized in the gene: for example in the rpoB gene for resistance to rifampicin, or in the katG, inhA or kasA gene for resistance to isoniazid.
- the point mutation is localized in the rpoB gene (gene for the subunit b of RNA polymerase).
- Table 1 presents a list of capture probes targeting different mutational positions within the rpoB gene in M. tuberculosis.
- Table 1 Sequences of the probes targeting wild and mutated genotypes detected at the level of the rpoB gene. The numbering in italics is linked to the first numbering of the codons in function of the Escherichia coli genome. The numbering in bold is linked to the new codon nomenclature, based on the genome of Mycobacterium tuberculosis.
- the point mutation is localized in the katG gene (heme-containing enzyme catalase-peroxidase), in the kasA gene (3-oxoacyl-ACP synthase) or in the promoter region of the inhA gene (enoyl-acyl carrier protein reductase gene).
- table 2 presents a list of capture probes targeting different mutational positions within the katG and inhA genes in M. tuberculosis.
- Table 2 Sequences of the probes targeting wild and mutated genotypes detected at the level of the katG and inhA genes.
- the method according to the invention allows the detection of mononucleic polymorphisms within the genus Enterovirus and thus allows grouping at the diagnostic level, in particular for a simultaneous diagnosis of Enteroviruses and Rhinoviruses (species belonging to the genus Enterovirus).
- the present invention also relates to an oligochromatographic support on which specific capture probes are immobilized.
- the oligochromatographic support and the capture probes are as defined above.
- said support comprises a capture probe complementary and specific to the wild sequence of the target region and at least one capture probe complementary and specific to the mutated sequence of the target region.
- the present invention also relates to a microfluidic device comprising the oligochromatographic support according to the invention.
- the microfluidic device is as described in European Patent EP 2 870 260.
- the present invention finally relates to a reagent kit comprising at least primers for amplification of a target region and the oligochromatographic support according to the invention.
- Figure 1 Schematic representation of amplicon hybridization and amplicon labeling systems.
- Figure 2 Schematic representation of capture probes immobilized on the oligochromatographic support: checkerboard of 40 spots and example of 4 capture probes including the one with the wild genotype; probe 1 has a mutation in position 5 (G> C), probe 2 has a mutation in position 5 (G> T) and probe 3 has a mutation in position 4 (A> G).
- Figure 3 Microfluidic device described in European Patent EP 2 870 260.
- Figure 4 Histogram illustrating the detection of a strain of Mycobacterium tuberculosis mutated in position 526 and wild for positions 511-512-513; 516; 522; 529; 531; 533 at the level of the rpoB gene.
- Figure 5 Histogram illustrating the detection of a strain of Mycobacterium tuberculosis mutated at position 315 at the level of the katG gene.
- Figure 6 Histogram illustrating the specific detection of Enterovirus and Rhinovirus species.
- rifampicin resistance to rifampicin is due to one or more (mono) nucleotide polymorphisms in the rpoB gene (gene for the subunit b of RNA polymerase, target of rifampicin in Mycobacterium tuberculosis).
- the amplicon_l has 9 mutational positions and the amplicon_2 has a single mutational position. From 2 to 6 sequence variants are detected for each of the positions (Table 1).
- the target regions of the rpoB gene of Mycobacterium tuberculosis are amplified by PCR, followed by detection on an oligochromatographic support, in the microfluidic device as described in patent application EP 3075451.
- the buffer tank (12) is filled with a volume of buffered washing solution which can range from 50 to 80 ⁇ L.
- the reaction mixture tank (11) is filled with a volume of 10 to 20 ⁇ l of reaction mixture containing the sample and the amplification reagents, and, if appropriate, reverse transcription.
- Closing of the device the microfluidic device is hermetically closed by a pump head (Patent application EP 3075451).
- the device is inserted into appropriate dedicated equipment allowing the steps of reverse transcription, PCR amplification, hybridization of the amplification products to the probes immobilized on the oligochromatography device and washing of the reading area with buffered washing solution.
- the composition of the amplification buffer is as follows: Titanium®Taq DNA polymerase kit (Takara) containing IX Titanium Taq PCR Buffer and 1.25X Titanium taq DNA polymerase, supplemented with 1.5 mM MgCl2, dNTPs 0, 8 mM, BSA 0.6 mg / mL, PEG, 1.5%, Betaine IM, DMSO 5% and the four primers for amplifying amplicons 1 and 2.
- the PCR product (amplified DNA) present in the amplification buffer will reach the region of application (lower absorbent) of the oligochromatographic strip.
- the liquid (amplification buffer comprising the PCR product) will then migrate through this absorbent and reach the nitrocellulose membrane at the level of which the capture probes are deposited.
- the PCR product present in the amplification buffer will migrate entirely by capillarity in the membrane.
- the membrane is then washed with the washing / migration buffer which will follow the same path as the PCR product at the microfluidic chip.
- the hybridization and washing steps have a total duration of approximately 20 minutes and the total reaction time (amplification + hybridization + washing) is between 60 and 75 minutes. Hybridization takes place at a temperature of 71 ° C.
- the device is managed by dedicated equipment allowing the management of the flow of the liquid in the channel of the microfluidic device via an active pumping system and the management of the temperature of at least two, and up to 5, heating zones under the reaction mixture tank, amplification chamber and PCR channel and a heating zone under the detection rod.
- the results are interpreted by the dedicated equipment analysis software.
- the identification of the wild or mutated character of each position of interest is carried out by the analysis of the fluorescence values between probes hybridizing at the same positions.
- amino acids For example, for position 526/445 of the rpoB gene, 6 amino acids have been identified in natural variants: histidine (H) in the wild sequence, aspartate (D), asparagine (N), tyrosine (Y), leucine (L) or arginine (R) in mutated variants. Each of these amino acid changes is due to a mutation in the corresponding codon.
- the amplification product hybridizes to each of these 6 probes and the signal intensity is measured.
- the signal is related to the average of the signals of the 5 other probes.
- the signal ratios thus calculated make it possible to identify the genotype at the position considered: the probe for which a signal ratio greater than the pre-determined cut-off value (for example the value 2) is obtained corresponds to the sequence present in the 'sample.
- the genotype is wild for positions 511-512-513-522-529-531 and 533 (identified by a ratio greater than 2, dark gray histogram bars) and the genotype is mutated H526Y (black bar) for position 526 (nomenclature of F. coli) ( Figure 4).
- the light gray bars represent the ratio obtained for each of the probes which correspond to the wild-type H526 and to the mutants not detected. ( Figure 4).
- the amino acid change is identified.
- the histidine at position 526 is replaced by a tyrosine; amino acids at other positions are wild type.
- This method also makes it possible to detect mixtures of strains or variants.
- the protocol for the reverse transcription, amplification, hybridization and washing steps can be transposed from example 1.
- the hybridization and washing steps have a total duration of approximately 20 minutes and the total reaction time (amplification + hybridization + washing) is between 60 and 75 minutes.
- Hybridization takes place at a temperature of 71 ° C.
- a target sequence of 85 nucleotides was therefore selected at the level of the katG gene and a sequence of 123 nucleotides was selected at the level of the inhA gene (Table 4).
- inhA gene the different mutational positions are found in the promoter region of the gene. A mutation at this level therefore does not induce the formation of a new amino acid but the overexpression of the gene which will lead to resistance to isoniazid.
- the target regions of the katG gene and of the promoter region of the inhA gene of Mycobacterium tuberculosis are amplified separately by PCR, followed by detection on an oligochromatographic support in the microfluidic device, as described in the previous example .
- the results are interpreted by the dedicated equipment analysis software.
- the mutational position 315 can present 4 different amino acids: the serine (S) which corresponds to the wild sequence, threonine (T), found in two of the mutated sequences, asparagine ( N) and isoleucine (I). Each of these amino acid changes is due to a mutation in the corresponding codon.
- S serine
- N threonine
- I isoleucine
- the amplification product hybridizes to each of these 5 probes and the signal strength is measured. For each probe, the signal is related to the average of the signals of the 4 other probes.
- the signal ratios thus calculated allow the genotype to be identified at the position considered: the probe for which a signal ratio greater than a predetermined cut-off is obtained corresponds to the sequence present in the sample.
- the genotype for position 315 is mutated S315N (nomenclature of F. coli).
- the light gray bars represent the ratio obtained for each of the probes which correspond to undetected wild and mutant genotypes ( Figure 5).
- the amino acid change is identified.
- the serine is replaced by an asparagine.
- the protocol for the reverse transcription, amplification, hybridization and washing steps can be transposed from example 1.
- the hybridization and washing steps have a total duration of approximately 20 minutes and the total reaction time (amplification + hybridization + washing) is between 60 and 75 minutes.
- Hybridization takes place at a temperature between 50 ° C and 66 ° C.
- the detection of (mono) nucleotide polymorphisms was evaluated on genetic material mimicking sequences of the genus Enterovirus.
- the genus Enterovirus includes 12 species including 9 Enteroviruses (A to H and J) and 3 Rhinoviruses (A to C). Some Enteroviruses cause respiratory symptoms, similar to Rhinoviruses. This clinical similarity, as well as their belonging to the same phylogenetic group, allows grouping at the diagnostic level. A conserved region within this Enterovirus genus was therefore selected for a simultaneous diagnosis of Enteroviruses / Rhinoviruses. Two subspecies, enterovirus A and Rhinovirus C were then selected to demonstrate the differentiation of two sequences with only a G / A difference basis (Table 5).
- the target sequences of these two subspecies were detected specifically by tube oligochromathography after being amplified by PCR.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE20185469A BE1026457B1 (fr) | 2018-07-04 | 2018-07-04 | Procédé et dispositif pour la détection et différenciation de mutations ponctuelles chez des microorganismes par oligochromatographie |
PCT/EP2019/068046 WO2020008009A1 (fr) | 2018-07-04 | 2019-07-04 | Procede et dispositif pour la detection et differenciation de mutations ponctuelles chez des microorganismes par oligochromatographie |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3818181A1 true EP3818181A1 (fr) | 2021-05-12 |
Family
ID=63014284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19734437.7A Pending EP3818181A1 (fr) | 2018-07-04 | 2019-07-04 | Procede et dispositif pour la detection et differenciation de mutations ponctuelles chez des microorganismes par oligochromatographie |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3818181A1 (fr) |
BE (1) | BE1026457B1 (fr) |
WO (1) | WO2020008009A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117327821A (zh) * | 2023-11-09 | 2024-01-02 | 上海市肺科医院(上海市职业病防治院) | 对超低比例利福平耐药突变定量检测的试剂盒及检测方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7101672B2 (en) * | 1998-05-05 | 2006-09-05 | Third Wave Technologies, Inc. | Target-dependent reactions using structure-bridging oligonucleotides |
EP1076099A3 (fr) * | 1999-08-03 | 2003-03-05 | Nisshinbo Industries, Inc. | Trousse pour la diagnose des bacilles de tubercule |
US6642000B1 (en) * | 1999-11-12 | 2003-11-04 | University Of Chicago | PCR amplification on microarrays of gel immobilized oligonucleotides |
ES2363501T3 (es) | 2003-05-07 | 2011-08-05 | Coris Bioconcept Sprl | Dispositivo oligocromático de un paso y procedimiento de uso. |
GB0428255D0 (en) * | 2004-12-23 | 2005-01-26 | Health Prot Agency | Detection of nucleic acid mutations |
RU2376387C2 (ru) * | 2005-12-26 | 2009-12-20 | Учреждение Российской академии наук Институт молекулярной биологии им. В.А. Энгельгардта РАН | Способ одновременного обнаружения микобактерий туберкулезного комплекса и идентификации мутаций в днк микобактерий, приводящих к устойчивости микроорганизмов к рифампицину и изониазиду, на биологических микрочипах, набор праймеров, биочип и набор олигонуклеотидных зондов, используемые в способе |
ES2582602T3 (es) * | 2007-03-28 | 2016-09-14 | Signal Diagnostics | Sistema y método de análisis de alta resolución de ácidos nucleicos para detectar variaciones de secuencia |
US20140302486A1 (en) * | 2011-09-02 | 2014-10-09 | President And Fellows Of Harvard College | Systems and methods for detecting biomarkers of interest |
BE1020816A5 (fr) | 2012-07-04 | 2014-05-06 | Coris Bioconcept Sprl | Procede et dispositif pour la detection rapide de sequences nucleotidiques amplifiees. |
EP3075451B1 (fr) | 2015-03-31 | 2020-05-13 | Coris Bioconcept SPRL | Dispositif de puce d'écoulement jetable |
CN109219667B (zh) * | 2016-02-15 | 2023-02-28 | 安普诊断公司 | 诊断装置及相关方法 |
-
2018
- 2018-07-04 BE BE20185469A patent/BE1026457B1/fr active IP Right Grant
-
2019
- 2019-07-04 WO PCT/EP2019/068046 patent/WO2020008009A1/fr unknown
- 2019-07-04 EP EP19734437.7A patent/EP3818181A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020008009A1 (fr) | 2020-01-09 |
BE1026457A1 (fr) | 2020-01-30 |
BE1026457B1 (fr) | 2020-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2789689B1 (fr) | Amorces chimères avec des conformations en épingle à cheveux et leurs procédés d'utilisation | |
JP2004506431A5 (fr) | ||
CN107435067B (zh) | 用于在核酸测定中改善熔链分辨和多重性的探针 | |
KR20120017033A (ko) | 반응 카트리지에서의 다중 핵산 서열의 검출 | |
JP2013081450A (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット | |
JP2013090622A (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット | |
JP2018528780A (ja) | 短いホモポリマー反復の改良された検出 | |
US10392652B2 (en) | Micro RNA detection method using two primers to produce an amplified double stranded DNA fragment having a single stranded region at one end | |
JP2013048620A (ja) | メチシリン耐性黄色ブドウ球菌を検出するためのプライマーおよびプローブ、ならびに、それらを用いたメチシリン耐性黄色ブドウ球菌の検出方法 | |
EP3818181A1 (fr) | Procede et dispositif pour la detection et differenciation de mutations ponctuelles chez des microorganismes par oligochromatographie | |
US20220162686A1 (en) | Membrane-based, in-gel loop-mediated isothermal amplification (lamp) system and method for detecting microbes | |
KR101068605B1 (ko) | Nat2 유전자 증폭용 프라이머 셋트, 그것을 포함하는 nat2 유전자 증폭용 시약 및 그 용도 | |
JP5613160B2 (ja) | ゲノムdna中の標的配列の検出又は解析方法 | |
WO2016158898A1 (fr) | Procédé de détection d'une mutation de gène et oligonucléotide marqué par fluorescence l'utilisant | |
CN109182563B (zh) | 检测20种dfrA类甲氧苄胺嘧啶类药物耐药基因的方法及所用试剂盒 | |
WO2021152257A1 (fr) | Procede de genotypage hla simple et rapide | |
EP2235218B1 (fr) | Methode, procede, et kit de diagnostic, pronostic du cancer colorectal | |
Zhang et al. | Multiple thermocycles followed by LAMP with only two primers for ultrasensitive colorimetric viral RNA testing and tracking at single-base resolution | |
EP1254253B1 (fr) | Oligonucleotides monocatenaires, sondes, amorces et procede de detection des spirochetes | |
Lee et al. | Development and clinical evaluation of a microarray for HLA‐A and‐DRB1 genotyping | |
CN109312397A (zh) | Penta E基因座多态性人体鉴定 | |
FR2911144A1 (fr) | Methode d'obtention d'un profil genetique specifique d'une variete d'orge a l'aide de couples d'amorces. | |
JP6911308B2 (ja) | CTX−M型基質特異性拡張型β−ラクタマーゼ遺伝子の検出方法 | |
EP4097255A1 (fr) | Procede de pcr multiplexe pour la detection de microorganismes et son utilisation | |
EP1137804A1 (fr) | METHODE DE DETECTION $i(IN VITRO) D'UNE SUBSTANCE CABLE DANS UN ECHANTILLON COMPRENANT LE MARQUAGE DE LADITE SUBSTANCE PAR UN GENE RAPPORTEUR ET PAR LES SEQUENCES NECESSAIRES A L'EXPRESSION DUDIT GENE RAPPORTEUR IN VITRO |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210204 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: AVRAIN, LAETITIA Inventor name: NAZE, FLORENCE Inventor name: MERTENS, PASCAL Inventor name: LEFEVRE, OLIVIA Inventor name: LECLIPTEUX, THIERRY |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
PUAG | Search results despatched under rule 164(2) epc together with communication from examining division |
Free format text: ORIGINAL CODE: 0009017 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230508 |
|
B565 | Issuance of search results under rule 164(2) epc |
Effective date: 20230508 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12Q 1/689 20180101AFI20230502BHEP |